About
Technology
Issues
FAQ
Links
Official Page
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.